Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Prostate Cancer treatment details. Biologic therapy. Chemotherapy. The University of Texas MD Anderson Cancer Center, Houston, TX, United States



Survival: 21.5 months
   
Toxicity Grade: 5
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Houston, TX
   
Hospital: The University of Texas MD Anderson Cancer Center
   
Journal: Link
   
Date: 12/2013

Description:
Patients:
This phase 3 study involved chemotherapy-naive, metastatic, castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 762 patients with a median age of 69 years, while group B had 760 patients with a median age of 68 years.

Treatment:
Patients in group A were treated with the chemotherapy agent docetaxel and the biologic therapy agent dasatinib (a Src kinase inhibitor that interferes with cancer cell growth and tumor metastases).

Patients in group B were given docetaxel chemotherapy.

Toxicities:
Treatment-related deaths due to febrile neutropenia, septic shock, cerebral hematoma (bleeding), and respiratory and cardio-respiratory failure were reported in group A. Grade 4 diarrhea and fatigue were also reported.

Treatment-related deaths due to infection, heart failure, and kidney failure were reported in group B. Grade 4 diarrhea and back pain were also reported.

Results:
The median overall survival times for groups A and B were 21.5 and 21.2 months, respectively.

Support:
This study was supported by Bristol-Myers Squibb (makers of dasatinib).

Correspondence: Dr. John C Araujo; email: johna@mdanderson.org

E-mail to a Friend Email Physician More Information